FIGURE 1




FIGURE 2

Influence of Y1-Dimer on platelets aggregation (PRP)-Ristocetin activation

Date	Clone	concentration ug/ml	Aggregation before	% aggragation before	% aggragation after
6.2.02	washed platelet	30	3	20	70
10.3.02	Dimer CysKAK	25	4.5	30	87
11.3.02	Dimer CysKAK	25	8	61	
13.3.02	Dimer pool-024-118	25	14	100	
			Average n=3	63%	
6.2.02	washed platelet	7.5	2.5	17	72
10.3.02	Dimer CysKAK	10	4	27	87
11.3.02	Dimer CysKAK	10	8	61	
13.3.02	Dimer pool-024-118	10	9	61	
			Average n=3	50%	87
6.2.02	washed platelet	7.5	2.5	17	72
10.3.02	Dimer CysKAK	4	2	13	67
13.3.02	Dimer pool-024-118	4	2	13	90
			Average n=2	13%	78%
6.2.02	washed platelet	0.5	1	22	81
10.3.02	Dimer CysKAK	1	0	0	
11.3.02	Dimer CysKAK	1	0	0	
13.3.02	Dimer pool-024-118	1	0	0	
			Average n=3	0%	

FIGURE 3



AN51-PE
R1
SSC
FSC
R1
FSC
FL2-H
Negative Control
0.25ug Y1-myc+
0.25ug Y1
FSC
FL1-H
0.25ug L32
0.25ug TM1.1

FIGURE 4



Key Name
NO1-biotin
Y1-biotag + NO1
Y1-biotag + Y1 MYC+
Y1-biotag + L32
A: 0 ng
B: 100 ng
C: 250 ng
D: 500 ng
E: 1000 ng
F: 2500 ng
G: 5000 ng
Counts
FL2-H
A
B
C
D
E
F
G

FIGURE 5



Geo mean y1 biotag (50ng)
0
10
20
30
40
50
60
Competitor concentration (ng)
0
100
250
500
1000
2500
5000
N01
P01
L32

FIGURE 6



% Relative binding
0
20
40
60
80
100
120
5 Y1
10 Y1
15 Y1
20 Y1
5 Y1(myc+)
10 Y1(myc+)
15 Y1(myc+)
20 Y1(myc+)
5 L32
10 L32
15 L32
20 L32
5 TM1.1
10 TM1.1
15 TM1.1
20 TM1.1
Antibody
Y1 and L32binding to GC

FIGURE 7




FIGURE 8



% Relative binding
0
20
40
60
80
100
120
C
I
J
P1 (K)
P28S
A
B
M
N
O
E
G
P1S
P14S
(L)
Peptide
5ug/ml TM1.1-myc+
20ug/ml TM1.1-myc+
5ug/ml Y1
20ug/ml Y1
5ug/ml L32
20ug/ml L32

FIGURE 9



% Reduction in the geo mean of Y17 binding to platelets
0
10
20
30
40
50
60
70
80
90
100
P1 (K)
P1S (L)
P2S
P25S
P28S
Peptide added
200 uM
25 uM
2.5 uM

FIGURE 10



Binding to peptide (OD 450 nm)
0
0,5
1
1,5
2
2,5
3
G
I
Peptide
5ug/ml Y1
20ug/ml Y1
5ug/ml Y17
20ug/ml Y17

FIGURE 11A



Binding of FITC-TM1 to cells
% gated cells
0
10
20
30
40
50
0
0.5
1
1.5
2
2.5
µg TM1.1
T-ALL
N-PBL

FIGURE 11B



Binding of FITC-TM13 to cells
% gated cells
0
10
20
30
40
50
0
0.5
1
1.5
2
2.5
µg TM3.13
T-ALL
N-PBL

FIGURE 11C



% gated cells
0
20
40
60
80
100
0
100
200
300
400
500
600
ng L-32
T-ALL
N-PBL
Binding of scFv L-32(crude) to cells

FIGURE 12A




Liver weight (gr)
0
0,5
1
1,5
2
2,5
3
PBS (no tumor)
Molt-4 (untreated)
Y1 (0.2 mg)
L32 (0.2 mg)

FIGURE 12B


Prevalence (according to histological assessment)
0%
10%
20%
30%
40%
50%
60%
70%
PBS (no tumor)
Molt-4 (untreated)
Y1 (0.2 mg)
L32 (0.2 mg)
0%
65%
10%
18%